Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06510530 | Astragalus for Symptomatic Alleviation in High-grade Lymphoma | not yet recruiting | Phase 3 | 60 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06500507 | A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 90 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03422393 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | active not recruiting | Phase 1 | 24 | Michael ChoiOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma(CARMAN) | recruiting | Phase 2 | 150 | Christian Schmidt, MDOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06482931 | Bleeding in Multiple Myeloma(BiMM) | not yet recruiting | — | 160 | University Medical Center GroningenOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06472479 | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 66 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06463717 | Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not | recruiting | — | 210 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06454968 | Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05775224 | ASH Research Collaborative Data Hub | enrolling by invitation | — | 100,000 | ASH Research CollaborativeOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06461182 | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma(PentixaFor) | recruiting | Phase 2 | 15 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | recruiting | Early Phase 1 | 10 | Shanghai Changzheng HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06450821 | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications | not yet recruiting | N/A | 60 | University of LeedsOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06439173 | Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment | recruiting | — | 40 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06436677 | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma(AMITY) | recruiting | — | 100 | Peking University First HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT06149910 | Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma | recruiting | — | 450 | All4CureINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | active not recruiting | Phase 1 | 90 | Cullinan Therapeutics Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT06376214 | Daratumumab for Patients With Light Chain Amyloidosis | recruiting | N/A | 100 | Nanjing University School of MedicineOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | not yet recruiting | — | 260 | Peking University People's HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06366802 | Cohort Construction and Prognostic Model Construction for Multiple Myeloma | active not recruiting | — | 1,000 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) | recruiting | — | 5,300 | Paolo CorradiniOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | not yet recruiting | Phase 1 / Phase 2 | 166 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06318884 | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 76 | Sinocelltech Ltd.INDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2024source: clinicaltrials